C07D 211/96
Sulfur atom
C07D211/96 (Sulfur atom) appears on 461 US grants and 597 published applications in this corpus.
Search patents in C07D- Granted patents
- 461
- Published applications
- 597
- Assignees
- 315
- Inventors
- 1,922
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 8 | 0 |
| 1977 | 2 | 0 |
| 1978 | 5 | 0 |
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 4 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 4 | 0 |
| 1995 | 3 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 3 | 0 |
| 1999 | 6 | 0 |
| 2000 | 5 | 0 |
| 2001 | 13 | 5 |
| 2002 | 15 | 17 |
| 2003 | 16 | 23 |
| 2004 | 12 | 29 |
| 2005 | 12 | 39 |
| 2006 | 18 | 36 |
| 2007 | 18 | 16 |
| 2008 | 11 | 23 |
| 2009 | 15 | 29 |
| 2010 | 16 | 33 |
| 2011 | 13 | 28 |
| 2012 | 22 | 17 |
| 2013 | 24 | 32 |
| 2014 | 21 | 29 |
| 2015 | 31 | 29 |
| 2016 | 20 | 25 |
| 2017 | 20 | 21 |
| 2018 | 17 | 24 |
| 2019 | 18 | 18 |
| 2020 | 16 | 17 |
| 2021 | 12 | 17 |
| 2022 | 11 | 22 |
| 2023 | 6 | 20 |
| 2024 | 11 | 18 |
| 2025 | 10 | 20 |
| 2026 | 5 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Substituted cyclohexyl compounds as NOP inhibitors2 Jun 2026US 12,643,888 B2Dart NeuroScience, LLC
- Opioid receptor agonist, preparation method therefor and pharmaceutical use thereof12 May 2026US 12,624,004 B2Fudan University
- Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency28 Apr 2026US 12,611,402 B2Centessa Pharmaceuticals (UK) Limited
- Probenecid compounds for the treatment of inflammasome-mediated lung disease17 Mar 2026US 12,577,211 B2Bacainn Biotherapeutics, Ltd.
- Processes and compounds for the decarboxylative amination of redox-active esters with diazirines10 Mar 2026US 12,570,611 B2H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Cyclohexyl or heterocycloalkyl beta-hydroxy alkyl amines for use in the treatment of hyperglycaemia and disorders characterised by hyperglycaemia17 Sep 2026US 2026/0274785 A1Atrogi AB
- Heterocycloalkyl beta-hydroxy alkyl amines for use in the treatment of hyperglycaemia and disorders characterised by hyperglycaemia20 Aug 2026US 2026/0242335 A1Atrogi AB
- N,n'-sulfonimidamides as anticancer, antiinflammatory, antifibrotic and neuroprotective agents20 Aug 2026US 2026/0242349 A1Atux Iskay LLC
- Chemical coupling linker and use thereof13 Aug 2026US 2026/0232832 A1
- Compounds as soluble epoxide hydrolase inhibitors9 Jul 2026US 2026/0193176 A1Universitat De Barcelona
Most cited
By later US patents
- Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors218US 5,861,510 APfizer Inc. · 1999
- Heterocyclo inhibitors of potassium channel function120US 7,005,436 B2Bristol-Myers Squibb Company · 2006
- Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof91US 8,129,519 B22012
- Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases71US 8,563,735 B2AbbVie Inc. · 2013
- Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla60US 7,067,665 B2Sanofi-Aventis Deutschland GmbH · 2006